在第二次多中心选择性淋巴结切除术试验 (MSLT-II) 后，随着淋巴结监测越来越多地用于前哨淋巴结阳性 (SLN) 黑色素瘤，高质量的淋巴结超声检查 (U/S) 已成为迫切需要。先前的工作表明，很少使用 MSLT-II U/S 标准来定义需要干预或活检的异常淋巴结。为了解决这一差距，在这项单中心研究中设计并实施了基于证据的概要模板。回顾性鉴定了 2017 年 7 月至 2023 年 6 月在三级癌症中心接受淋巴结监测的前哨淋巴结阳性患者。对超声报告语言进行了分析，以了解报告的 MSLT-II 标准和临床可行的建议（例如，正常、异常并建议进行活检）。经过多学科设计流程，概要模板于 2023 年 1 月实施。通过使用美国报告和提供者调查来评估实施后的结果。总共对 94 名 SLN 患者进行了 337 项美国研究，中位数为 3 U每个患者 /S（范围 1-12）。在实施后执行的 42 个符合天气条件的 U/S 中，有 32 个 U/S (76.0%) 进行了天气情况报告。报告的 MSLT-II 标准数量显着增加（前 0.5 ± 0.8 对比后 2.5 ± 1.0，p < 0.001），以及针对异常结果的临床可行建议（前 64.0% 对比后 93.0%，p = 0.04） ）。几乎所有外科医生和放射科医生的调查受访者都对概要模板的临床实用性感到“非常”或“完全”满意 (90.0%)。实施概要模板后，美国报告更有可能记录 MSLT-II 标准并提供可行的建议，增加对提供商的有用性。正在努力向其他中心传播此概要模板。© 2024。作者。

With nodal surveillance increasingly used for sentinel lymph node-positive (SLN+) melanoma following the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II), high-quality nodal ultrasonography (U/S) has become a critical need. Previous work has demonstrated low utilization of MSLT-II U/S criteria to define abnormal lymph nodes requiring intervention or biopsy. To address this gap, an evidence-based synoptic template was designed and implemented in this single-center study.Sentinel lymph node-positive patients undergoing nodal surveillance at a tertiary cancer center from July 2017 to June 2023 were identified retrospectively. Ultrasound reporting language was analyzed for MSLT-II criteria reported and clinically actionable recommendations (e.g., normal, abnormal with recommendation for biopsy). Following a multidisciplinary design process, the synoptic template was implemented in January 2023. Postimplementation outcomes were evaluated by using U/S reports and provider surveys.A total of 337 U/S studies were performed on 94 SLN+ patients, with a median of 3 U/S per patient (range 1-12). Among 42 synoptic-eligible U/S performed postimplementation, 32 U/S (76.0%) were reported synoptically. Significant increases were seen in the number of MSLT-II criteria reported (Pre 0.5 ± 0.8 vs. Post 2.5 ± 1.0, p < 0.001), and clinically actionable recommendations for abnormal findings (Pre 64.0% vs. Post 93.0%, p = 0.04). Nearly all surgeon and radiologist survey respondents were "very" or "completely" satisfied with the clinical utility of the synoptic template (90.0%).Following implementation of a synoptic template, U/S reports were significantly more likely to document MSLT-II criteria and provide an actionable recommendation, increasing usefulness to providers. Efforts to disseminate this synoptic template to other centers are ongoing.© 2024. The Author(s).